Search Results - "Kalkers, N. F."

Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS by HUIJBREGTS, S. C. J, KALKERS, N. F, DE SONNEVILLE, L. M. J, DE GROOT, V, REULING, I. E. W, POLMAN, C. H

“…To investigate the cognitive skills of patients with relapsing remitting multiple sclerosis (RRMS), secondary progressive MS (SPMS), and primary progressive MS…”
Get full text

Safety, tolerability, and efficacy of orally administered cannabinoids in MS by KILLESTEIN, J, HOOGERVORST, E. L. J, REIF, M, KALKERS, N. F, VAN LOENEN, A. C, STAATS, P. G. M, GORTER, R. W, UITDEHAAG, B. M. J, POLMAN, C. H

“…The authors conducted a randomized, double-blind, placebo-controlled, twofold crossover study in 16 patients with MS who presented with severe spasticity to…”
Get full text

The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study by Kalkers, N F, Barkhof, F, Bergers, E, van Schijndel, R, Polman, C H

“…Progressive axonal loss is the most likely pathologic correlate of irreversible neurologic impairment in primary progressive multiple sclerosis. In a run-in…”
Get full text

A longitudinal study of cognition in primary progressive multiple sclerosis by Camp, S. J., Stevenson, V. L., Thompson, A. J., Ingle, G. T., Miller, D. H., Borras, C., Brochet, B., Dousset, V., Falautano, M., Filippi, M., Kalkers, N. F., Montalban, X., Polman, C. H., Langdon, D. W.

“…There are few longitudinal studies of cognition in patients with multiple sclerosis, and the results of these studies remain inconclusive. No serial…”
Get full text

Anxiety and depression influence the relation between disability status and quality of life in multiple sclerosis by JANSSENS, A. C. J. W, VAN DOORN, P. A, DE BOER, J. B, KALKERS, N. F, VAN DER MECHE, F. G. A, PASSCHIER, J, HINTZEN, R. Q

“…Disability status, depression and anxiety are important determinants of quality of life (QoL) in patients with multiple sclerosis (MS). We investigated whether…”
Get full text

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients by van Lierop, ZYGJ, Toorop, AA, Coerver, EME, Willemse, EAJ, Strijbis, EMM, Kalkers, NF, Moraal, B, Barkhof, F, Teunissen, CE, Killestein, J, van Kempen, ZLE

“…Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our…”
Get full text

Optimizing the association between disability and biological markers in MS by KALKERS, N. F, BERGERS, E, CASTELIJNS, J. A, VAN WALDERVEEN, M. A. A, BOT, J. C. J, ADER, H. J, POLMAN, C. H, BARKHOF, F

“…Axonal damage is an important feature of MS pathology and the likely substrate of development of progressive disability. Brain volume measurement on MRI can be…”
Get full text

Long-term clinical outcome of primary progressive MS : Predictive value of clinical and MRI data by SASTRE-GARRIGA, J, INGLE, G. T, BARKHOF, F, BROCHET, B, DOUSSET, V, FILIPPI, M, MONTALBAN, X, KALKERS, N. F, POLMAN, C. H, ROVIRA, A, MILLER, D. H, THOMPSON, A. J, ROVARIS, M, TELLEZ, N, JASPERSE, B, ALTMANN, D. R, BENEDETTI, B, STEVENSON, V. L, CERCIGNANI, M, LEARY, S. M

“…The authors sought to identify clinical and MRI predictors of outcome in primary progressive multiple sclerosis (PPMS). Clinical and MRI assessments were…”
Get full text

The Brief Repeatable Battery of Neuropsychological Tests: normative values allow application in multiple sclerosis clinical practice by Boringa, J.B., Lazeron, R.H.C., Reuling, I.E.W., Adèr, H.J., Pfennings, L.E.M.A., Lindeboom, J., de Sonneville, L.M.J., Kalkers, N.F., Polman, C.H.

“…The Brief Repeatable Battery of Neuropsychological Tests (BRB-N) is a sensitive measure of cognitive impairment in multiple sclerosis (MS) patients. It…”
Get full text

Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue by Kalkers, N F, Vrenken, H, Uitdehaag, B MJ, Polman, C H, Barkhof, F

“…Introduction: In multiple sclerosis (MS), brain atrophy measurement on magnetic resonance imaging (MRI) reflects overall tissue loss, especially demyelination…”
Get full text

Motor evoked potential: A reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI by Kalkers, N.F, Strijers, R.L.M, Jasperse, M.M.S, Neacsu, V, Geurts, J.J.G, Barkhof, F, Polman, C.H, Stam, C.J

“…Abstract Objective In an attempt to analyze whether MEP can serve as a valid measure for evaluating neurological dysfunction in multiple sclerosis (MS), we…”
Get full text

The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite by HOOGERVORST, E. L. J, KALKERS, N. F, CUTTERS, G. R, UITDEHAAG, B. M. J, POLMAN, C. H

“…To prospectively characterize the relation between two-year changes in functional impairment as measured by the Multiple Sclerosis Functional Composite (MSFC)…”
Get full text

MS Functional Composite : Relation to disease phenotype and disability strata by KALKERS, N. F, DE GROOT, V, LAZERON, R. H. C, KILLESTEIN, J, ADER, H. J, BARKHOF, F, LANKHORST, G. J, POLMAN, C. H

“…The MS Functional Composite (MSFC), a recently developed outcome measure for clinical trials, was applied to 240 patients with MS to explore its utility in…”
Get full text

Comparisons of patient self-report, neurologic examination, and functional impairment in MS by HOOGERVORST, E. L. J, VAN WINSEN, L. M. L, EIKELENBOOM, M. J, KALKERS, N. F, UITDEHAAG, B. M. J, POLMAN, C. H

“…To compare the recently developed Guy's Neurologic Disability Scale (GNDS), based on patient self-report, with both neurologist rating of neurologic…”
Get full text

Concurrent validity of the MS Functional Composite using MRI as a biological disease marker by KALKERS, N. F, BERGERS, L, DE GROOT, V, LAZERON, R. H. C, VAN WALDERVEEN, M. A. A, UITDEHAAG, B. M. J, POLMAN, C. H, BARKHOF, F

“…The MS Functional Composite (MSFC), a recently developed outcome measure for MS clinical trials measuring three dimensions (ambulation/leg function, arm/hand…”
Get full text

Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial by Toorop, A.A., Wessels, M.H.J., Gelissen, L.M.Y., Hoitsma, E., Zeinstra, E.M.P.E., van Rooij, L.C., van Munster, C.E.P., Vennegoor, A., Mostert, J.P., Wokke, B.H.A., Kalkers, N.F., Hoogervorst, E.L.J., van Eijk, J.J.J., Roosendaal, C.M., Kragt, J.J., Eurelings, M., van Genugten, J., Nielsen, J., Sinnige, L.G.F., Kloosterziel, M.E., Arnoldus, E.P.J., van Dijk, G.W., Bouvy, W.H., Strijbis, E.M.M., van Oosten, B.W., de Jong, B.A., Lissenberg-Witte, B.I., Rispens, T., Uitdehaag, B.M.J., Killestein, J., van Kempen, Z.L.E.

“…Wearing-off symptoms during natalizumab treatment in multiple sclerosis are characterized by an increase of MS-related symptoms prior to natalizumab…”
Get full text

Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy by Kalkers, N.F., Hintzen, R.Q., van Waesberghe, J.H.T.M., Lazeron, R.H.C., van Schijndel, R.A., Adèr, H.J., Polman, C.H., Barkhof, F.

“…Introduction: Magnetization transfer ratio (MTR) histogram analysis can be used as a method for quantifying overall disease burden in MS. We studied…”
Get full text

Two-year follow-up study of primary and transitional progressive multiple sclerosis by Ingle, G T, Stevenson, V L, Miller, D H, Leary, S M, Rovaris, M, Barkhof, F, Brochet, B, Dousset, V, Filippi, M, Montalban, X, Kalkers, N F, Polman, C H, Rovira, A, Thompson, A J

“…This study documents changes in clinical and magnetic resonance imaging (MRI) characteristics in a large cohort of patients with primary and transitional…”
Get full text

Cross-sectional and longitudinal correlations between the Arm Function in Multiple Sclerosis Questionnaire (AMSQ) and other outcome measures in multiple sclerosis by Molenaar, P.C.G., Strijbis, E.M.M., van Munster, C.E.P., Uitdehaag, B.M.J., Kalkers, N.F.

“…•The arm function in multiple sclerosis questionnaire (AMSQ) shows moderate correlations with established physician- and performance based outcome measures in…”
Get full text

Multiple sclerosis functional composite: impact of reference population and interpretation of changes by Uitdehaag, B MJ, Adèr, H J, Roosma, T JA, de Groot, V, Kalkers, N F, Polman, C H

“…The Multiple sclerosis functional composite (MSFC) has been recommended as a clinical outcome measure to be used in future MS trials. A specific characteristic…”
Get full text